Quantum BioPharma News - August 2026
🟢 Quantum BioPharma is trading 10.78% up today after positive Moderna and Merck Phase 3 melanoma-vaccine results
Quantum BioPharma is trading 10.78% up at $3.78 after a broad biotech-sector rally following positive Moderna and Merck Phase 3 melanoma-vaccine results. -...
🟢 Quantum BioPharma is trading 8.98% up today as positive Moderna trial results lift the biotech sector
Quantum BioPharma is trading at $3.64 (up 8.98%), gaining alongside a broader biotech sector rally triggered by positive Moderna cancer-vaccine trial results...
🔴 Quantum BioPharma is trading 10.05% down today as risk-off sentiment pressures speculative stocks
Quantum BioPharma is trading 10.05% down now at $3.31 as broader risk-off sentiment pressures speculative stocks. - The Nasdaq Composite is down 1.35%, while...
🔴 Quantum BioPharma is trading 9.78% down today amid apparent broader risk-off trading
Quantum BioPharma is trading at $3.33 (-9.78%) now, amid what appears to be broader risk-off trading. - August 17, 2026, second-quarter results showed...
🟢 Quantum BioPharma is trading 12.61% up in pre-market after FDA approval for Lucid-MS Phase 2
Quantum BioPharma is trading at $4.28 (+12.61%) in pre-market after FDA approval of an IND allowing Lucid-MS to advance into Phase 2. - The randomized,...
🟢 Quantum BioPharma is trading 8.4% up in pre-market after FDA approval for Lucid-MS Phase 2
Quantum BioPharma is trading 8.43% up now at $4.12 after momentum continued from its August 14, 2026 Q2 results and FDA approval to advance Lucid-MS into a...
🟢 Quantum BioPharma Surges 11.46% After Strong Q2 Results and FDA Clearance for Lucid-MS Phase 2
Quantum BioPharma is trading at $3.60 (+11.46%) today, following the release of robust Q2 2026 financial results and the recent FDA clearance for Lucid-MS to...
🟢 Quantum BioPharma is trading 5% up today after Q2 results and stronger liquidity
Quantum BioPharma is trading 5.11% up now at $3.40 after reporting second-quarter 2026 results and stronger liquidity on August 14, 2026. - Reported...
🔴 Quantum BioPharma is trading 10.34% down today with no fresh company-specific catalyst identified
Quantum BioPharma is trading 10.34% down at $3.12 with no fresh company-specific catalyst identified for August 13, 2026. - The latest major announcement was...
🟢 Quantum BioPharma is trading 8.38% up in pre-market after FDA cleared Lucid-MS for Phase 2 development
Quantum BioPharma is trading 8.38% up at $3.75 after the FDA approved its Investigational New Drug application for Lucid-MS on August 10, 2026, allowing the...
🟢 Quantum BioPharma is trading 12.75% up today after FDA cleared Lucid-MS IND for Phase 2 trial
Quantum BioPharma is trading 12.75% up now at $3.89 after the FDA cleared its Investigational New Drug application for Lucid-MS, enabling a Phase 2 trial for...
Quantum BioPharma Clears a Key FDA Hurdle for Its MS Drug — But Can a Micro-Cap Turn One Green Light Into Real Value?
Shares of Quantum BioPharma Ltd. surged as much as 7.5% to $3.71 after the company announced the FDA cleared its investigational new drug (IND) application for...
🟢 Quantum BioPharma is trading 7.54% up today after FDA approval of Lucid-MS IND
Quantum BioPharma is trading at $3.71 (+7.54%) after the FDA approved Quantum BioPharma’s IND application for Lucid-MS. - The clearance enables the company to...
🟢 Quantum BioPharma is trading 10.84% up today amid biotech sentiment
Quantum BioPharma is trading at $3.55 (+10.84%), with broader biotech sentiment supported by argenx’s $2.2 billion Forte Biosciences acquisition. • No...
🟢 Quantum BioPharma is trading 11.38% up today as biotech M&A speculation lifts sector
Quantum BioPharma is trading 11.38% up at $3.23, with biotech-sector strength providing the clearest explanation for the August 6, 2026 move. - The XBI...
🔴 Quantum BioPharma is trading 8.2% down today in a reversal of recent gains
Quantum BioPharma is trading at $2.80 (-8.20%) today, giving back a portion of the prior session’s 5.54% gain. • The decline appears to be driven by intraday...
Quantum BioPharma Ltd. Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
For the second quarter of 2026, analysts anticipate Quantum BioPharma will report a consensus revenue of $1.90 million and an earnings per share loss of $0.51,...